174 related articles for article (PubMed ID: 8996206)
1. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates.
Huang NY; Kostrzewa RM; Li C; Perry KW; Fuller RW
J Pharmacol Exp Ther; 1997 Jan; 280(1):268-76. PubMed ID: 8996206
[TBL] [Abstract][Full Text] [Related]
2. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
3. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment.
Brus R; Kostrzewa RM; Perry KW; Fuller RW
J Pharmacol Exp Ther; 1994 Jan; 268(1):231-7. PubMed ID: 8301563
[TBL] [Abstract][Full Text] [Related]
4. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
[TBL] [Abstract][Full Text] [Related]
5. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system.
Gong L; Kostrzewa RM; Fuller RW; Perry KW
J Pharmacol Exp Ther; 1992 Jun; 261(3):1000-7. PubMed ID: 1602367
[TBL] [Abstract][Full Text] [Related]
6. Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity.
Kostrzewa RM; Gong L; Brus R
Acta Neurobiol Exp (Wars); 1993; 53(1):31-41. PubMed ID: 8317265
[TBL] [Abstract][Full Text] [Related]
7. Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats.
Huang NY; Kostrzewa RM
Eur J Pharmacol; 1994 Dec; 271(2-3):433-7. PubMed ID: 7705443
[TBL] [Abstract][Full Text] [Related]
8. Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system.
Kostrzewa RM; Brus R; Perry KW
Pol J Pharmacol; 1999; 51(1):39-47. PubMed ID: 10389143
[TBL] [Abstract][Full Text] [Related]
9. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
10. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements.
Sasaki T; Kennedy JL; Nobrega JN
Psychopharmacology (Berl); 1996 Nov; 128(1):97-104. PubMed ID: 8944412
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine.
Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842
[TBL] [Abstract][Full Text] [Related]
12. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
[TBL] [Abstract][Full Text] [Related]
13. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats.
See RE; Chapman MA; Meshul CK
Synapse; 1992 Oct; 12(2):147-54. PubMed ID: 1362290
[TBL] [Abstract][Full Text] [Related]
14. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 1. Dopaminergic neurons and receptors.
Yokoyama C; Okamura H
J Pharmacol Exp Ther; 1997 Feb; 280(2):1016-30. PubMed ID: 9023319
[TBL] [Abstract][Full Text] [Related]
15. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
16. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
17. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
19. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
20. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Joyce JN
Synapse; 2001 May; 40(2):137-44. PubMed ID: 11252025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
